TY - JOUR T1 - Comprehensive mycotoxin exposure biomonitoring in breastfed and non-exclusively breastfed Nigerian children JF - medRxiv DO - 10.1101/2020.05.28.20115055 SP - 2020.05.28.20115055 AU - Chibundu N. Ezekiel AU - Wilfred A. Abia AU - Dominik Braun AU - Bojan Šarkanj AU - Kolawole I. Ayeni AU - Oluwawapelumi A. Oyedele AU - Emmanuel C. Michael-Chikezie AU - Victoria C. Ezekiel AU - Beatrice Mark AU - Chinonso P. Ahuchaogu AU - Rudolf Krska AU - Michael Sulyok AU - Paul C. Turner AU - Benedikt Warth Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/02/2020.05.28.20115055.abstract N2 - BACKGROUND Infants are a vulnerable population whose nutrition changes as complementary foods are introduced; a process which may modify patterns of exposure to dietary mycotoxins. However, exposure monitoring of dietary mycotoxin mixtures in several biological samples obtained from breastfed and non-exclusively breastfed children is scarce.OBJECTIVES To examine mycotoxin co-exposure patterns in infants using a multi-specimen, multi-mycotoxin approach.METHODS Breast milk, complementary food and urine obtained from 65 infants, aged 1–18 months, in Ogun state, Nigeria, were analyzed for mycotoxins using ultra-sensitive LC-MS/MS approaches.RESULTS Complementary food was contaminated with seven distinct classes of mycotoxins including aflatoxins (9/42 samples; range: 1.0–16.2µg/kg) and fumonisins (14/42; range: 8– 167µg/kg). Aflatoxin M1 was detected in breast milk (4/22), while six other classes of mycotoxins were quantified; including dihydrocitrinone (6/22; range: 14.0–59.7ng/L) and sterigmatocystin (1/22; 1.2ng/L) detected for the first time. Mycotoxins were detected in 64/65 of the urine samples, with seven distinct classes of mycotoxins observed demonstrating ubiquitous exposure. Two aflatoxin metabolites (AFM1 and AFQ1) and FB1 were detected in 6/65, 44/65 and 17/65 samples, respectively. Mixtures of mycotoxin classes were common, including 14/42, 22/22 and 56/65 samples having 2–4, 2–6 or 2–6 mycotoxins present, for complementary food, breast milk and urine, respectively. Aflatoxin and/or fumonisin was detected in 12/14, 4/22 and 46/56 for complimentary foods, breast milk and urine, respectively. Furthermore, the detection frequency, mean concentrations and occurrence of mixtures were typically greater in urine of non-exclusively breastfed compared to breastfed children.CONCLUSIONS The study provides novel insights into mycotoxin co-exposures in children in a mycotoxin high-risk country without proper food safety measures. Albeit a small sample set, it highlights significant transition to higher levels of infant mycotoxin exposure as complementary foods are introduced, providing impetus to mitigate during this critical early-life period and encourage breastfeeding.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors want to gratefully acknowledge the Mass Spectrometry Centre (MSC) of the Faculty of Chemistry at the University of Vienna and Sciex for providing mass spectrometric instrumentation to BW. This work was performed with the financial support of the University of Vienna, the City of Vienna Jubilee Funds (BOKU Research Funding, project MycoMarker) and the Austrian Science Fund (FWF): P 33188-B.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical permission for this study was granted by the Babcock University Health Research Ethics Committee under two approval numbers: BUHREC294/16 for the EB children and BUHREC156/15 for the NEB children.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData in this study are available on request. ER -